

March 6, 2026

PRIOR AUTHORIZATION UPDATE FOR MEDICAL REVIEW GUIDELINE: CHANGED EFFECTIVE DATE & FORM

SUMMARY OF NOTIFICATION

Community previously posted updated criteria for authorization of glucagon like peptide-1 (GLP1) medications for Marketplace to go live 4/1/2026, however this **date has changed to 5/1/2026**. The corresponding prior authorization form can now be found on our website, but please note that it should not be used until 5/1/2026.

This pertains to the following products:

- Bydureon (exenatide)
- Byetta (exenatide)
- Exenatide
- Liraglutide
- Mounjaro (tirzepatide)
- Ozempic (semaglutide)
- Rybelsus (semaglutide)
- Trulicity (dulaglutide)
- Victoza (liraglutide)

KEY DETAILS

Please find the glucagon like peptide-1 (GLP1) prior authorization form [here](#) and the corresponding GLP-1 Medical Review Guideline outlining the criteria, located on our [Community Provider Website](#) under the “Prior Authorization Requests: Essential Information & Supporting Clinical Documentation” section.